Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Chlorothiazide
Drug ID BADD_D00442
Description A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Indications and Usage Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Marketing Status approved; vet_approved
ATC Code C03AA04
DrugBank ID DB00880
KEGG ID D00519
MeSH ID D002740
PubChem ID 2720
TTD Drug ID D0M9WM
NDC Product Code 42419-007; 12828-0005; 38779-3147; 33656-0012; 65649-311; 59605-1745; 57821-001
UNII 77W477J15H
Synonyms Chlorothiazide
Chemical Information
Molecular Formula C7H6ClN3O4S2
CAS Registry Number 58-94-6
SMILES C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005; 23.03.03.094--
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003---
Pneumonitis22.01.01.006--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Renal failure20.01.03.005---
Respiratory distress22.02.01.012---
Restlessness17.02.05.021; 19.11.02.002--
Sialoadenitis07.06.04.002; 11.01.04.002--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Thrombocytopenia01.08.01.002---
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Urticaria10.01.06.001; 23.04.02.001--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Vasculitis10.02.02.006; 24.12.04.027--
Vasculitis necrotising10.02.02.008; 24.12.04.029---
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Xanthopsia06.02.05.002---
Tubulointerstitial nephritis20.05.02.002---
Epigastric discomfort07.01.02.004---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages